SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10945)11/10/1997 4:29:00 PM
From: Andrew H  Read Replies (1) | Respond to of 32384
 
Ok Henry, let me list some of the news we are expecting from LGND by the end of the year. Perhaps you can fill in what I leave out.

1. the loooong awaited leptin deal.

2. the drug to be selected from LLY.

3. the three articles you are expecting.

4. Panretin trials for KS.

5. Panretin trials for psoriasis.

6. ALRT 1550 trials

7. Targretin oral and topical for CTCL

8. Targretin for lung cancer

We may not get all of these in the next 50 days and some may come early next Q, but I would be interested in your timetable estimates. Anything I left out?



To: Henry Niman who wrote (10945)11/11/1997 1:58:00 AM
From: chirodoc  Read Replies (2) | Respond to of 32384
 
<<<<<<< The Barron's article on AMLN really didn't have anything new, but I do expect it to attract some buyers. However, since nothing has changed, such jumps usually don't hold very long.

...it is competition nonetheless. and J&J is nothing to sneeze at--they are a very well managed company, imho.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News